IP Library › Granted Patent US 10,874,729
Granted Patent B2
US 10,874,729 · App. 16/458,726 · Granted Dec 29, 2020

Combination immunotherapy compositions against cancer and methods

Inventors: James Hodge (Kensington, MD); Jeffrey Schlom (Potomac, MD); Alex Franzusoff (Los Altos, CA)
Assignees: GlobeImmune, Inc.; The USA, as represented by the Secretary, Dept of Health and Human Services
A61K39/0011A61K39/00117A61K39/001102A61K39/001104A61K39/001106A61K39/001151A61K39/001152A61K39/001156A61K39/001157A61K39/001162A61K39/001164A61K39/001168A61K39/001182A61K39/001184A61K39/001186A61K39/001188A61K39/001191A61K39/001192A61K39/001194A61K39/001195A61K2039/523A61K2039/55522Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,729
App. No.
16/458,726
Granted
Dec 29, 2020
Kind
B2
Abstract

Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.

Claims (15)

1. A method to reduce tumor burden or inhibit tumor growth and/or to induce a therapeutic immune response against carcinoembryonic antigen (CEA) in an individual, comprising administering two immunotherapy compositions within one dosing of the individual in order to prime the immune system with each of the compositions, the two immunotherapy compositions comprising:

a) a first immunotherapy composition comprising a recombinant Ad5 adenovirus comprising a nucleic acid sequence encoding CEA or an immunogenic domain thereof; and

b) a second immunotherapy composition comprising a whole inactivated yeast or yeast lysate that has recombinantly expressed, prior to administration, CEA or an immunogenic domain thereof;

wherein the administration of the first and second immunotherapy compositions reduces tumor burden or inhibits tumor growth in the individual and/or induces a therapeutic immune response against CEA in the individual.

2. The method of claim 1 , wherein the whole inactivated yeast is a whole, heat-killed yeast.

3. The method of claim 1 , wherein the whole inactivated yeast is from Saccharomyces.

4. The method of claim 1 , wherein the first and second immunotherapy compositions are administered to different sites in the individual.

5. The method of claim 1 , wherein the first and second immunotherapy compositions are administered to the same site or to adjacent sites in the individual.

6. The method of claim 1 , wherein the CEA is human CEA.

7. The method of claim 6 , wherein the human CEA is full-length human CEA.

8. The method of claim 1 , wherein the CEA comprises a CAP1-6D epitope.

9. The method of claim 1 , further comprising boosting the individual with one or both of the immunotherapy compositions.

10. The method of claim 9 , wherein boosting the individual is with both immunotherapy compositions.

11. The method of claim 1 , further comprising boosting the individual with a third immunotherapy composition comprising a recombinant virus comprising the virus genome or portions thereof that is different from the first immunotherapy composition.

12. The method of claim 1 , wherein the individual is further treated with chemotherapy and/or with radiation therapy.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2019
From: FRANZUSOFF, ALEX
To: GLOBEIMMUNE, INC.
Reel/Frame 049863/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2019
From: SCHLOM, JEFFREY; HODGE, JAMES
To: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
Reel/Frame 049863/0289 →
Continuity (3)
Continuation 13264846
Provisional Application 61170530 · Apr 17, 2009
Related Publication 20200069784A1 · Mar 5, 2020